This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Blueprint Medicines (BPMC) Down 21.6% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) impresses investors with fourth-quarter earnings and revenue beat.
Deciphera's NDA for GIST Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
Blueprint Medicines' NDA for Avapritinib Gets Extended Review
by Zacks Equity Research
FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
by Zacks Equity Research
Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Blueprint Medicines Initiates Dosing in Liver Cancer Study
by Zacks Equity Research
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.
Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.
Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses
by Zacks Equity Research
Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.
Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.87% and 148.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance
by Zacks Equity Research
The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
by Zacks Equity Research
Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -6.25% and 80.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Blueprint Medicines (BPMC) Up 7.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines to File NDA for Avapritinib With FDA
by Zacks Equity Research
Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.
Blueprint Medicines' NDA for Avapritinib on Track for GIST
by Zacks Equity Research
Blueprint Medicines (BPMC) reports data on avapritinib from NAVIGATOR study for treating patients with PDGFRA Exon 18 mutant GIST and the fourth-line GIST.
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.